

AMENDMENTS TO THE CLAIMS

Listing of claims:

1.-3. (cancelled)

4. (currently amended) An endoprosthesis containing one or more of the elements from the group yttrium (Y), neodymium (Nd) or zirconium (Zr), wherein the endoprosthesis is adapted to be implanted in a vascular vessel and is adapted to inhibit the proliferation of human smooth muscle cells of the vascular vessel, and wherein the ~~formulation~~ endoprosthesis is adapted to liberate the one or more elements for intravascular liberation intravascularly after implantation in a vascular vessel and the ~~formulation~~ endoprosthesis includes an at least very substantially biodegradable carrier.

5.-6. (cancelled)

7. (previously presented) An endoprosthesis as set forth in claim 4, wherein the carrier is an alloy, selected from the group consisting of magnesium, iron and tungsten alloys.

8. (withdrawn) An endoprosthesis as set forth in claim 4 , wherein the carrier is a bioresorbable polymer and one or more of the elements selected from the group consisting of Y, Nd or Zr is embedded in the form of a powder or microparticles in the polymer.

9. (currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Y in a quantitative proportion of between 3.7 and 5.5 % by weight with respect to the total weight of the ~~formulation~~ endoprosthesis.

10. (withdrawn, currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Nd in a quantitative proportion of between 0.1 and 5% by weight with respect to the total weight of the ~~formulation~~ endoprosthesis.

11. (withdrawn, currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Zr in a quantitative proportion of between 0.1 and 3% by weight with respect to the total weight of the ~~formulation~~ endoprosthesis.

12. (currently amended) An endoprosthesis as set forth in claim 7, wherein the ~~formulation is~~ carrier comprises a magnesium alloy and contains Y in the range of between 3.7 and 5.5%, rare earths without Y in the range of between 1.5 and 4.4% by weight and remaining elements < 1%.

13. (currently amended) An endoprosthesis as set forth in claim 7 the ~~formulation is~~ carrier comprises a magnesium alloy and contains Y in the range of between 3.7 and 5.5% by weight, Nd in the range of between 1.8 and 2.7% by weight, and Zr in the range of between 0.2 and 1.2% by weight.

14. (previously presented) An endoprosthesis as set forth in claim 13, wherein the magnesium alloy is a WE43 alloy of the following formulation:

Zirconium in an amount of 0.53 % by weight,

Yttrium in an amount of 4.1 % by weight,

Neodymium in an amount of 2.2 % by weight, and

Magnesium in an amount greater than 92.77% by weight to 93.17 % by weight.

15. (currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Y and is so adapted that there is an yttrium concentration in the region of the human smooth muscle cells to be treated of between 200 μ M and 2 mM.

16. (withdrawn, currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Nd and is so adapted that there is a neodymium concentration in the region of the smooth muscle cells to be treated of between 600 μ M and 2 mM, in particular between 800 μ M and 1 mM.

17. (withdrawn, currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Zr and is so adapted that there is a zirconium concentration in the region of the smooth muscle cells to be treated of between 200 μ M and 2 mM, in particular between 200 μ M and 1 mM.

18. (withdrawn, currently amended) An endoprosthesis as set forth in claim 4, wherein the ~~formulation~~ endoprosthesis contains Y, Nd and Zr and is so adapted that there is an yttrium concentration of between 350 and 550 μ M, a neodymium concentration of between 100 and 200

μM and a zirconium concentration of between 10 and 30 μM in the region of the smooth muscle cells to be treated.

19.-25. (cancelled)